Cempra Receives Complete Response Letter From FDA For Solithromycin NDAs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Equities close higher as softer jobs data quiets rate-hike expectations
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Cempra (CEMP) Sees 21% 'Dead Cat Bounce'
December 30, 2016 10:42 AM ESTAfter plunging 57% on Thursday, Cempra (NASDAQ: CEMP) is making a fierce comeback today. Shares are up 21.2% today to $3.15, helped in part by an upgrade to Equalweight at Morgan Stanley. Morgan Stanley was negative into yesterday plunge on the back of ab FDA CRL for Solithromycin.
... MoreWBB Securities Downgrades Cempra, Inc. (CEMP) to Hold
December 29, 2016 1:40 PM ESTWBB Securities downgraded Cempra, Inc. (NASDAQ: CEMP) from Strong Buy to Hold with a price target of $4.00 (from $40.00) following today's CRL.
For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.
... MoreLadenburg Thalmann Downgrades Cempra, Inc. (CEMP) to Neutral
December 29, 2016 12:42 PM ESTLadenburg Thalmann downgraded Cempra, Inc. (NASDAQ: CEMP) from Buy to Neutral.
For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.
Shares of Cempra, Inc. closed at $6.10 yesterday.
... MoreMeaningful Commercial role for Cempra's (CEMP) Solithera 'Unlikely' - Needham & Company
December 29, 2016 11:45 AM ESTNeedham & Company analyst Alan Carr reiterated a Hold rating on Cempra, Inc. (NASDAQ: CEMP) after the FDA issued a CRL on Solithera.
Carr commented, "The agency reportedly informed company that safety profile of Solithera has not been adequately characterized and a larger safety... More
Cempra (CEMP) PT Slashed to $2 at Baird Amid CRL
December 29, 2016 9:13 AM ESTBaird analyst Brian Skorney reiterated an Underperform rating and slashed his price target on Cempra, Inc. (NASDAQ: CEMP) to $2.00 (from $6.00) following the FDA CRL.
Skorney commented, "With back-to-back PDUFA dates of the 27th/28th for oral/IV formulations of solithromycin, Cempra finally... More
